AstraZeneca PLC (AZN)

32.81
NYSE : Health Care
Prev Close 32.81
Day Low/High 0.00 / 0.00
52 Wk Low/High 25.55 / 35.60
Avg Volume 5.30M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 83.38B
EPS 1.40
P/E Ratio 14.77
Div & Yield 0.90 (2.70%)

Latest News

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

Wall Street starts the week with a rally.

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

The Dow is up more than 250 points.

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting

The world's biggest generic drug maker Monday named Kare Schultz as president and CEO, ending months of speculation about who would replace former head Erez Vigodman, who left the company in February for undisclosed reasons.

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Wall Street moves higher.

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results

AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results

AstraZencea shares topped London's FTSE 100 Monday after better-than-expected results in a key lung cancer treatment trial.

AstraZeneca Presents Superior Progression-Free Survival For IMFINZI® (durvalumab) In The Pacific Trial Of Patients With Locally-Advanced Unresectable Lung Cancer At ESMO 2017 Congress

AstraZeneca Presents Superior Progression-Free Survival For IMFINZI® (durvalumab) In The Pacific Trial Of Patients With Locally-Advanced Unresectable Lung Cancer At ESMO 2017 Congress

AstraZeneca and MedImmune, its global biologics research and development arm, today announced the full progression-free survival (PFS) data from a planned interim analysis of the investigational Phase III PACIFIC trial.

AstraZeneca's TAGRISSO® (osimertinib) Shows Potential As A New Standard Of Care In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer At ESMO 2017 Congress

AstraZeneca's TAGRISSO® (osimertinib) Shows Potential As A New Standard Of Care In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer At ESMO 2017 Congress

AstraZeneca today announced the full results of the Phase III FLAURA trial, which support TAGRISSO ®'s (osimertinib) clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with...

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma

Novel Investigational Drug is Designed to Block Thymic Stromal Lymphopoietin (TSLP) - An Upstream Driver of Inflammation in Asthma

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.

FASLODEX® (fulvestrant) Receives US FDA Approval As Monotherapy For Expanded Use In HR+, HER2- Advanced Breast Cancer

FASLODEX® (fulvestrant) Receives US FDA Approval As Monotherapy For Expanded Use In HR+, HER2- Advanced Breast Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved FASLODEX ® (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal...

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

LYNPARZA® (olaparib) Receives Additional FDA Approval In The US For Ovarian Cancer

LYNPARZA® (olaparib) Receives Additional FDA Approval In The US For Ovarian Cancer

AstraZeneca and Merck & Co., Inc.

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

The drug would be the first such treatment in Europe.

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of the hottest biotech stocks of the last month is selling off.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Acalabrutinib Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Mantle Cell Lymphoma

Acalabrutinib Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Mantle Cell Lymphoma

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for...

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

A glimpse of what to expect during Tuesday's pre-market.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

AstraZeneca Shares Just Fell Sharply, So Here Is Your Next Move

AstraZeneca Shares Just Fell Sharply, So Here Is Your Next Move

Big volume is hitting AstraZeneca and a breakout trade could trigger soon.

European Benchmarks Mixed as Investors Weigh Corporate Earnings and Economic Data

European Benchmarks Mixed as Investors Weigh Corporate Earnings and Economic Data

Higher inflation and, in some parts, solid corporate earnings were both factors on Monday.

Charter Says No to Sprint - 5 Things You Must Know Before the Market Opens

Charter Says No to Sprint - 5 Things You Must Know Before the Market Opens

U.S. stock futures rise Monday following a record closing high for the Dow Jones Industrial Average to end last week.

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation By US FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation By US FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI™ (durvalumab), an...

AstraZeneca Gets Breakthrough Designation For Imfinzi Following Pacific Trial

AstraZeneca Gets Breakthrough Designation For Imfinzi Following Pacific Trial

AstraZeneca's Imfinzi gets reprieve after MYSTIC failure

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

Shares lost more than 16% in London trading

TheStreet Quant Rating: B- (Buy)